Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P140010/S099

IN.PACT 018 Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter

Medtronic, Inc. · Decision date Aug 12, 2025

FDA DECISIONP140010/S099

What did the FDA decide?

FDA records P140010/S099 as a supplement to PMA P140010, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 12, 2025.

FDA approval order statement

transferring the balloon forming process from Medtronic Ireland to Medtronic Mexico for the IN.PACT 018 DCB
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Aug 12, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P140010/S099
Regulatory pathway
PMA supplement
Product code
ONU
Decision code
OK30
Decision date
Aug 12, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Drug-Eluting Peripheral Transluminal Angioplasty Catheter.

Product code
ONU
FDA device class
3

For the original device and its historical approval scope, see PMA P140010. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P140010 · Original PMA

    IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter and IN.PACT 018 Paclitax

  2. P140010/S099 received

    Application receipt date recorded by FDA.

  3. P140010/S097 · Related supplement

    IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter

  4. P140010/S099 · FDA decision

    30-Day Notice

  5. P140010/S100 · Related supplement

    IN.PACT Admiral Paclitaxelcoated PTA Balloon Catheter; IN.PACT 018 Paclitaxel-coated PTA Balloon Catheter

  6. P140010/S091 · Related supplement

    IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter and IN.PACT 018 Paclitax

  7. P140010/S101 · Related supplement

    IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter

  8. P140010/S098 · Related supplement

    IN.PACT 018 Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter

  9. P140010/S102 · Related supplement

    IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty Balloon Catheter; IN.PACT 018 Paclitaxel-Coated

  10. P140010/S103 · Related supplement

    IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter

  11. P140010/S104 · Related supplement

    IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty Balloon Catheter; IN.PACT 018 Paclitaxel-Coated

  12. P140010/S105 · Related supplement

    IN.PACT 018 Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PT A) Balloon Catheter

  13. P140010/S106 · Related supplement

    IN.PACT 018 Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter

Timeline entries are records held by MedtechLedger for P140010. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P140010

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA approvalDec 30, 2014FDA
Medtronic, Inc.PMA supplementAug 12, 2025FDA
Medtronic, Inc.PMA supplementSep 16, 2025FDA
Medtronic, Inc.PMA supplementJan 30, 2026FDA
Medtronic, Inc.PMA supplementFeb 13, 2026FDA
Medtronic, Inc.PMA supplementMar 6, 2026FDA
Medtronic, Inc.PMA supplementApr 23, 2026FDA
Medtronic, Inc.PMA supplementMay 1, 2026FDA
Medtronic, Inc.PMA supplementMay 21, 2026FDA
Medtronic, Inc.PMA supplementMay 28, 2026FDA
Medtronic, Inc.PMA supplementSep 24, 2026FDA

Explore the linked device profile

Other records with product code ONU

Product / regulatory recordCompanyPathwayDecision dateSource
BOSTON SCIENTIFIC CORPORATIONPMA supplementAug 4, 2026FDA
LutonixPMA supplementJul 9, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementMay 1, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementApr 24, 2026FDA
The Spectranetics Corp.PMA supplementMar 19, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
3576 Unocal Pl., Santa Rosa, CA, 95403

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records